The 3-month extension follows a major amendment to the NDA for the intrathecal cyclodextrin-based therapy, which has shown a 71% reduction in mortality risk in clinical trials.
MIT Technology Review welcomes pitches from freelance writers across a broad range of topics. We encourage writers of all skill levels, and from all backgrounds, to pitch us. We are especially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results